India's Obesity Drug Market Shifts Post-Novo Nordisk Patent Expiry

The entry of multiple generic weight-loss drugs after Novo Nordisk's patent expiration has increased competition, capturing a larger share of India's market. Eli Lilly's Mounjaro has seen a decrease in market presence, indicating competitive pressures. What's next is the potential for further generic drug entries and their impact on drug prices and access.